Bone Marrow Research最新文献_第3页

Angiogenesis and proliferation index in patients with acute leukemia: a prospective study. 急性白血病患者血管生成和增殖指数的前瞻性研究。

Bone Marrow Research Pub Date : 2014-01-01 Epub Date: 2014-03-31 DOI: 10.1155/2014/634874

Prabhavati Jothilingam, Debdatta Basu, Tarun K Dutta

{"title":"Angiogenesis and proliferation index in patients with acute leukemia: a prospective study.","authors":"Prabhavati Jothilingam, Debdatta Basu, Tarun K Dutta","doi":"10.1155/2014/634874","DOIUrl":"https://doi.org/10.1155/2014/634874","url":null,"abstract":"Angiogenesis and proliferation as measured by microvessel density (MVD) and proliferation index (PI) are essential correlates of malignancy. The aim of our study was to evaluate difference between these values in AML and ALL and also to study the modulation in these parameters following achievement of remission in acute lymphoblastic leukemia. Differences between adult and adolescent cases of acute leukemia in relation to these values were also studied. We also tried to assess the relationship between angiogenesis and proliferation. Fifty-five patients with acute leukemia were included in the study. Trephine biopsies were immunostained with CD34 and factor VIIIrAg to demonstrate angiogenesis measured as MVD. Immunostaining with PCNA and Ki-67 was done to study proliferation. We found a significant increase in MVD and PI in cases when compared with controls (P < 0.0001). In addition cases with ALL had a significantly higher MVD compared to those with AML (P < 0.01). The patients with ALL who went into remission showed a significant reduction in MVD; PI remained high. The cases which did not achieve remission showed no significant reduction in either MVD or PI. All adolescent cases of ALL were similar to adults with respect to MVD and PI. ","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/634874","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32319037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Bone marrow vascular niche: home for hematopoietic stem cells. 骨髓血管生态位:造血干细胞的家园。

Bone Marrow Research Pub Date : 2014-01-01 Epub Date: 2014-04-14 DOI: 10.1155/2014/128436

Ningning He, Lu Zhang, Jian Cui, Zongjin Li

引用次数: 65

Autologous Graft versus Host Disease: An Emerging Complication in Patients with Multiple Myeloma. 自体移植物抗宿主病:多发性骨髓瘤患者的新并发症

Bone Marrow Research Pub Date : 2014-01-01 Epub Date: 2014-05-04 DOI: 10.1155/2014/891427

Anu Batra, Michele Cottler-Fox, Terry Harville, Bobbie S Rhodes-Clark, Issam Makhoul, Mayumi Nakagawa

{"title":"Autologous Graft versus Host Disease: An Emerging Complication in Patients with Multiple Myeloma.","authors":"Anu Batra, Michele Cottler-Fox, Terry Harville, Bobbie S Rhodes-Clark, Issam Makhoul, Mayumi Nakagawa","doi":"10.1155/2014/891427","DOIUrl":"https://doi.org/10.1155/2014/891427","url":null,"abstract":"Autologous graft versus host disease (autoGVHD) is a rare transplant complication with significant morbidity and mortality. It has been hypothesized that patients with multiple myeloma might be predisposed to autoGVHD through dysregulation of the immune response resulting from either their disease, the immunomodulatory agents (IMiDs) used to treat it, or transplant conditioning regimen. Hematopoietic progenitor cell (HPC) products were available from 8 multiple myeloma patients with biopsy-proven autoGVHD, 16 matched multiple myeloma patients who did not develop autoGVHD, and 7 healthy research donors. The data on number of transplants prior to developing autoGVHD, mobilization regimens, exposure to proteasome inhibitors, use of IMiDs, and class I human leukocyte antigen types (HLA A and B) were collected. The HPC products were analyzed by flow cytometry for expression of CD3, CD4, CD8, CD25, CD56, and FoxP3. CD3(+) cell number was significantly lower in autoGVHD patients compared to unaffected controls (P = 0.047). On subset analysis of CD3(+) cells, CD8(+) cells (but not CD4(+) cells) were found to be significantly lower in patients with autoGVHD (P = 0.038). HLA-B55 expression was significantly associated with development of autoGVHD (P = 0.032). Lower percentages of CD3(+) and CD8(+) T-cells and HLA-B55 expression may be predisposing factors for developing autoGVHD in myeloma. ","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/891427","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32379559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

TET2 Inhibits Differentiation of Embryonic Stem Cells but Does Not Overcome Methylation-Induced Gene Silencing. TET2抑制胚胎干细胞分化，但不能克服甲基化诱导的基因沉默。

Bone Marrow Research Pub Date : 2014-01-01 Epub Date: 2014-08-25 DOI: 10.1155/2014/986571

Louis Norman, Paul Tarrant, Timothy Chevassut

{"title":"TET2 Inhibits Differentiation of Embryonic Stem Cells but Does Not Overcome Methylation-Induced Gene Silencing.","authors":"Louis Norman, Paul Tarrant, Timothy Chevassut","doi":"10.1155/2014/986571","DOIUrl":"https://doi.org/10.1155/2014/986571","url":null,"abstract":"TET2 is a methylcytosine dioxygenase that is frequently mutated in myeloid malignancies, notably myelodysplasia and acute myeloid leukemia. TET2 catalyses the conversion of 5'-methylcytosine to 5'-hydroxymethylcytosine within DNA and has been implicated in the process of genomic demethylation. However, the mechanism by which TET2 loss of function results in hematopoietic dysplasia and leukemogenesis is poorly understood. Here, we show that TET2 is expressed in undifferentiated embryonic stem cells and that its knockdown results in reduction of 5'-hydroxymethylcytosine in genomic DNA. We also present DNA methylation data from bone marrow samples obtained from patients with TET2-mutated myelodysplasia. Based on these findings, we sought to identify the role of TET2 in regulating pluripotency and differentiation. We show that overexpression of TET2 in a stably integrated transgene leads to increased alkaline phosphatase expression in differentiating ES cells and impaired differentiation in methylcellulose culture. We speculate that this effect is due to TET2-mediated expression of stem cell genes in ES cells via hydroxylation of 5'-methylcytosines at key promoter sequences within genomic DNA. This leads to relative hypomethylation of gene promoters as 5'-hydroxymethylcytosine is not a substrate for DNMT1-mediated maintenance methylation. We sought to test this hypothesis by cotransfecting the TET2 gene with methylated reporter genes. The results of these experiments are presented. ","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/986571","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32714534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple Myeloma. RAG模型:多发性骨髓瘤遗传风险分层的新范式。

Bone Marrow Research Pub Date : 2014-01-01 Epub Date: 2014-09-11 DOI: 10.1155/2014/526568

Steven M Prideaux, Emma Conway O'Brien, Timothy J Chevassut

{"title":"The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple Myeloma.","authors":"Steven M Prideaux, Emma Conway O'Brien, Timothy J Chevassut","doi":"10.1155/2014/526568","DOIUrl":"https://doi.org/10.1155/2014/526568","url":null,"abstract":"Molecular studies have shown that multiple myeloma is a highly genetically heterogonous disease which may manifest itself as any number of diverse subtypes each with variable clinicopathological features and outcomes. Given this genetic heterogeneity, a universal approach to treatment of myeloma is unlikely to be successful for all patients and instead we should strive for the goal of personalised therapy using rationally informed targeted strategies. Current DNA sequencing technologies allow for whole genome and exome analysis of patient myeloma samples that yield vast amounts of genetic data and provide a mutational overview of the disease. However, the clinical utility of this information currently lags far behind the sequencing technology which is increasingly being incorporated into clinical practice. This paper attempts to address this shortcoming by proposing a novel genetically based “traffic-light” risk stratification system for myeloma, termed the RAG (Red, Amber, Green) model, which represents a simplified concept of how complex genetic data may be compressed into an aggregate risk score. The model aims to incorporate all known clinically important trisomies, translocations, and mutations in myeloma and utilise these to produce a score between 1.0 and 3.0 that can be incorporated into diagnostic, prognostic, and treatment algorithms for the patient.","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/526568","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32729292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Human mesenchymal stromal cell-mediated immunoregulation: mechanisms of action and clinical applications. 人间充质间质细胞介导的免疫调节:作用机制和临床应用。

Bone Marrow Research Pub Date : 2013-01-01 Epub Date: 2013-09-29 DOI: 10.1155/2013/203643

Akaitz Dorronsoro, Jon Fernández-Rueda, Karoline Fechter, Izaskun Ferrin, Juan Manuel Salcedo, Emma Jakobsson, César Trigueros

引用次数: 35

Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin. 全淋巴细胞照射和抗胸腺细胞球蛋白非清髓性治疗后同种异体移植患者移植物抗宿主病的发病率和模式

Bone Marrow Research Pub Date : 2013-01-01 Epub Date: 2013-04-17 DOI: 10.1155/2013/414959

Lauren Veltri, Michael Regier, Aaron Cumpston, Sonia Leadmon, William Tse, Michael Craig, Mehdi Hamadani

{"title":"Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin.","authors":"Lauren Veltri, Michael Regier, Aaron Cumpston, Sonia Leadmon, William Tse, Michael Craig, Mehdi Hamadani","doi":"10.1155/2013/414959","DOIUrl":"https://doi.org/10.1155/2013/414959","url":null,"abstract":"Nonmyeloablative (NMA) conditioning with total lymphoid irradiation and antithymocyte globulin (TLI/ATG) has been shown to protect against acute graft-versus-host disease (GVHD). We report here our institutional experience with allogeneic transplantation following NMA conditioning with TLI/ATG (n = 21). GVHD prophylaxis consisted of a combination of a calcineurin inhibitor and mycophenolate mofetil. Median patient age was 59 years. The median followup of surviving patients is 545 days. One patient experienced primary graft rejection. The median time to neutrophil engraftment was 18 days and platelet engraftment was 9.5 days. The cumulative incidence (CI) of grade II-IV acute GVHD at day +100 was 28.6% and 38.1% at day +180. The CI for grade III-IV acute GVHD was 28.6% at day +180. CI of chronic GVHD was 45.2% at 1 year. The CI of disease relapse was 9.5% at 1 year. The rate of nonrelapse mortality (NRM) was 0% at day +100 and only 9.5% at 1 year. The overall and progression free survival at 1 year was 81% and 80.4%, respectively. Our limited, retrospective data show encouraging relapse and NRM rates with TLI/ATG-based NMA conditioning, but with higher than previously reported rates of acute and chronic GVHD, underscoring the need for novel strategies designed to effectively prevent GVHD.","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/414959","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31445159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Validation of the EBMT Risk Score for South Brazilian Patients Submitted to Allogeneic Hematopoietic Stem Cell Transplantation. 巴西南部接受同种异体造血干细胞移植患者EBMT风险评分的验证

Bone Marrow Research Pub Date : 2013-01-01 Epub Date: 2013-12-12 DOI: 10.1155/2013/565824

Beatriz Stela Pitombeira, Alessandra Paz, Annelise Pezzi, Bruna Amorin, Vanessa Valim, Alvaro Laureano, Andrea Wieck, Lisandra Rigoni, Erica Ottoni, Gustavo Fisher, Liane Daudt, Lucia Silla

{"title":"Validation of the EBMT Risk Score for South Brazilian Patients Submitted to Allogeneic Hematopoietic Stem Cell Transplantation.","authors":"Beatriz Stela Pitombeira, Alessandra Paz, Annelise Pezzi, Bruna Amorin, Vanessa Valim, Alvaro Laureano, Andrea Wieck, Lisandra Rigoni, Erica Ottoni, Gustavo Fisher, Liane Daudt, Lucia Silla","doi":"10.1155/2013/565824","DOIUrl":"https://doi.org/10.1155/2013/565824","url":null,"abstract":"Background. Allogeneic hematopoietic stem cell transplantation (HSCT) is still associated with a high transplant-related mortality rate. In 2009, the EBMT risk score was validated as a simple tool to predict the outcome after allogeneic HSCT for acquired hematological disorders. Objectives. The aim of this study was to validate the applicability of the EBMT risk score for allogeneic HSCT on South Brazilian patients. Methods. A retrospective observational study was performed based on patients' records and data base at Hospital de Clínicas de Porto Alegre, including all allogeneic transplants for malignant and severe aplastic anemia from 1994 to 2010. Patients were categorized according to EBMT risk score and overall survival (OS). Nonrelapse mortality (NRM) and relapse rate (RR) were analyzed. Results. There were 278 evaluable patients. OS, NRM, and RR at five years median followup were 48.7%, 40.7%, and 30.7%, respectively. The OS was 81.8% for risk score 0 and 0% for score 6 (P < 0.001), and NRM was 13.6% and 80% for risk scores 0 and 6, respectively (P = 0.001). Conclusion. The EBMT risk score can be utilized as a tool for clinical decision making before allogeneic HSCT for malignant hematological diseases and severe aplastic anemia at a single center in Brazil. ","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/565824","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32023079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Adenoviral Delivery of the VEGF and BMP-6 Genes to Rat Mesenchymal Stem Cells Potentiates Osteogenesis. 腺病毒向大鼠间充质干细胞传递VEGF和BMP-6基因促进成骨。

Bone Marrow Research Pub Date : 2013-01-01 Epub Date: 2013-02-26 DOI: 10.1155/2013/737580

Jesse Seamon, Xiuli Wang, Fuai Cui, Tom Keller, Abhijit S Dighe, Gary Balian, Quanjun Cui

{"title":"Adenoviral Delivery of the VEGF and BMP-6 Genes to Rat Mesenchymal Stem Cells Potentiates Osteogenesis.","authors":"Jesse Seamon, Xiuli Wang, Fuai Cui, Tom Keller, Abhijit S Dighe, Gary Balian, Quanjun Cui","doi":"10.1155/2013/737580","DOIUrl":"https://doi.org/10.1155/2013/737580","url":null,"abstract":"The combined delivery of mesenchymal stem cells (MSCs), vascular endothelial growth factor (VEGF), and bone morphogenetic protein (BMP) to sites of bone injury results in enhanced repair compared to the administration of a single factor or a combination of two factors. Based on these findings, we hypothesized that coexpression of VEGF and BMP-6 genes would enhance the osteoblastic differentiation of rat bone-marrow-derived stem cells (rMSCs) and osteogenesis by comparison to rMSCs that do not express VEGF and BMP-6. We prepared a GFP tagged adenovirus vector (Ad-VEGF+BMP-6) that contained DNA encoding the hVEGF and hBMP-6 genes. rMSCs were transduced with the virus, and the successful transduction was confirmed by green fluorescence and by production of VEGF and BMP-6 proteins. The cells were cultured to assess osteoblastic differentiation or administered in the Fischer 344 rats to assess bone formation. Mineralization of rMSCs transduced with Ad-VEGF+BMP-6 was significantly enhanced over the nontransduced rMSCs. Only transduced rMSCs could induce osteogenesis in vivo, whereas Ad-VEGF+BMP-6 or nontransduced rMSCs alone did not induce osteogenesis. The data suggests that the combined delivery of MSCs, VEGF, and BMP-6 is an attractive option for bone repair therapy.","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/737580","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40229802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17

High-Frequency Vibration Treatment of Human Bone Marrow Stromal Cells Increases Differentiation toward Bone Tissue. 高频振动治疗人骨髓基质细胞促进向骨组织分化。

Bone Marrow Research Pub Date : 2013-01-01 Epub Date: 2013-03-25 DOI: 10.1155/2013/803450

D Prè, G Ceccarelli, L Visai, L Benedetti, M Imbriani, M G Cusella De Angelis, G Magenes

{"title":"High-Frequency Vibration Treatment of Human Bone Marrow Stromal Cells Increases Differentiation toward Bone Tissue.","authors":"D Prè, G Ceccarelli, L Visai, L Benedetti, M Imbriani, M G Cusella De Angelis, G Magenes","doi":"10.1155/2013/803450","DOIUrl":"https://doi.org/10.1155/2013/803450","url":null,"abstract":"In order to verify whether differentiation of adult stem cells toward bone tissue is promoted by high-frequency vibration (HFV), bone marrow stromal cells (BMSCs) were mechanically stimulated with HFV (30 Hz) for 45 minutes a day for 21 or 40 days. Cells were seeded in osteogenic medium, which enhances differentiation towards bone tissue. The effects of the mechanical treatment on differentiation were measured by Alizarin Red test, (q) real-time PCR, and protein content of the extracellular matrix. In addition, we analyzed the proliferation rate and apoptosis of BMSC subjected to mechanical stimulation. A strong increase in all parameters characterizing differentiation was observed. Deposition of calcium was almost double in the treated samples; the expression of genes involved in later differentiation was significantly increased and protein content was higher for all osteogenic proteins. Lastly, proliferation results indicated that stimulated BMSCs have a decreased growth rate in comparison with controls, but both treated and untreated cells do not enter the apoptosis process. These findings could reduce the gap between research and clinical application for bone substitutes derived from patient cells by improving the differentiation protocol for autologous cells and a further implant of the bone graft into the patient.","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/803450","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31357351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 29